Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection -A Tertiary Hospital based study
Phase 3
- Registration Number
- CTRI/2020/03/024402
- Lead Sponsor
- Dr Remesh Bhasi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Moderate to high risk of exposure to infected patients during the study period.
2. Healthy at the time of enrolment without any symptoms suggestive of any viral infection.
Exclusion Criteria
1. History of known allergy to Hydro ChloroQuine(HCQ) or Chloroquine
2. Known contraindications for HCQ or Chloroquine including Retinopathy, known Cardiac disease like Dysarrythmias, and G6PD deficiency.
3. Pregnancy and Lactation
4. History of recent (within one month) International travel.
5. Features of any ongoing infection including COVID-19
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method